Skip to content

    AbCellera Biologics (ABCL) stock price & financials

    View ABCL earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+160.9% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $6.51M
    $5.05M
    $4.24M
    $17.08M
    $8.96M
    +37.6%
    $44.85M
    +788.4%
    $8.31M
    +96.3%
    $4.05M
    -76.3%
    Strengthening
    Operating Profit
    -$93.66M
    -$72.75M
    -$62.66M
    -$49.59M
    -$76.28M
    +18.6%
    -$28.58M
    +60.7%
    -$57.52M
    +8.2%
    -$62.78M
    -26.6%
    Strengthening
    Net Profit
    -$51.11M
    -$34.21M
    -$45.62M
    -$34.73M
    -$57.12M
    -11.8%
    -$8.95M
    +73.9%
    -$43.16M
    +5.4%
    -$55.43M
    -59.6%
    Strengthening
    EPS
    $-0.17
    $-0.15
    $-0.12
    $-0.19
    -11.8%
    $-0.14
    +6.7%
    $-0.18
    -50.0%
    Weakening
    Other Income
    $31.03M
    $25.93M
    $9.68M
    $13.24M
    $7.51M
    -75.8%
    $9.08M
    -65.0%
    $7.98M
    -17.5%
    $3.81M
    -71.2%
    Weakening
    Interest
    Depreciation
    Profit before Tax
    -$62.63M
    -$46.83M
    -$52.98M
    -$36.34M
    -$68.77M
    -9.8%
    -$19.50M
    +58.4%
    -$49.54M
    +6.5%
    -$58.97M
    -62.2%
    Stable
    MarginsOPM
    -1439.4%
    -1441.0%
    -1479.6%
    -290.2%
    -851.8%
    +40.8%
    -63.7%
    +95.6%
    -691.8%
    +53.2%
    -1550.0%
    -434.1%
    Weakening
    Tax
    18.4%
    26.9%
    13.9%
    4.5%
    16.9%
    -7.9%
    54.1%
    +100.9%
    12.9%
    -7.5%
    6.0%
    +34.8%
    Strengthening
    ReturnsROIC
    -7.4%
    -4.9%
    -6.6%
    -5.0%
    -8.2%
    -11.8%
    -1.3%
    +73.9%
    -6.2%
    +5.4%
    -8.0%
    -59.6%
    Strengthening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$594.12M$476.14M$386.54M$133.32M$156.32M$128.51M$120.06M
    Short-Term Investments
    Total Current Assets$813.33M$929.80M$1.03B$871.99M$751.37M$728.23M$679.23M
    Net PP&E$17.92M$111.62M$298.09M$73.14M$66.65M$136.12M$131.82M
    Goodwill$31.50M$47.81M$47.81M$47.81M$47.81M$47.81M$47.81M
    Intangibles$0$115.15M$148.39M$131.50M$120.42M$42.11M$38.38M$36.53M
    Total Assets$1.01B$1.32B$1.54B$1.49B$1.36B$1.36B$1.31B
    LiabilitiesTotal Current Liabilities$103.49M$120.68M$118.32M$119.01M$76.61M$64.31M$53.19M
    Short-Term Debt$190.0K
    Long-Term Debt
    Long-Term Leases$3.71M$36.41M$76.67M$71.22M$60.74M$137.40M$129.95M
    Total Liabilities$175.03M$292.84M$307.63M$335.78M$304.47M$390.05M$411.56M
    EquityCommon Stock & APIC$710.39M$722.43M$734.37M$753.20M$777.17M$802.34M$821.24M
    Retained Earnings$114.20M$267.67M$426.19M$279.79M$116.93M-$29.48M-$128.07M
    Total Equity$10.25M$830.51M$1.03B$1.23B$1.15B$1.06B$966.90M$896.02M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating$2.69M$22.69M$244.58M$277.36M-$43.88M-$108.56M-$131.29M-$94.94M
    Cash from Investing-$5.78M-$119.78M-$332.25M-$352.63M-$221.11M$121.41M$87.75M$97.89M
    Cash from Financing$195.0K$683.65M-$3.89M-$1.63M$10.36M$12.77M$14.08M$25.07M
    SummaryCapital Expenditure-$4.00M-$9.67M-$58.45M-$70.66M-$76.95M-$78.40M-$42.77M-$24.73M
    Free Cash Flow-$1.30M$13.02M$186.13M$206.70M-$120.82M-$186.95M-$174.07M-$119.67M
    FCF Margin-11.2%5.6%49.6%42.6%-317.7%-648.4%-231.7%-180.8%

    Ratios